Recent News

Optimal Timing of Surgical Resection for NSCLC

2019 STS: Novel Predictive Tool for Prolonged Air Leak After Lung Cancer Surgery

2019 STS: Imaging Nanoagent for Sentinel Lymph Node Mapping in Lung Surgery

2019 STS: How Socioeconomic Status Impacts Outcomes in Non–Small Cell Lung Cancer

2019 STS: Impact of Regionalization of Lung Cancer Surgery on Outcomes

2019 STS: Stage Correlation, Guideline-Concordant Care, and Survival in NSCLC

FDA Accepts sBLA for Atezolizumab Plus Chemotherapy in First-Line Treatment of Metastatic NSCLC

2019 STS: Opioid Use Varies Among Elderly After Lung Resection

FDA Expands Pemetrexed Indication With Pembrolizumab and Chemotherapy in First-Line Treatment of NSCLC

2019 STS: Can Patients Over Age 90 Benefit From NSCLC Treatment?

Academic vs. Community-Based Centers: Survival Disparities Among Patients With NSCLC?

KEYNOTE-010 in Advanced NSCLC: Long-Term Survival Benefit With Pembrolizumab

How Accurate Are NCDB Comorbidity Assessments in Lung Cancer and Other Resected Tumors?

OAK Trial: Disease Progression With Atezolizumab vs Chemotherapy in NSCLC

First-Line Immunotherapy Combination in Lung Cancer

Early Research of Birabresib in Lung Cancer and Other Solid Tumors

Is More Frequent Surveillance Associated With Better Survival for Patients With NSCLC?

FDA Approves Atezolizumab Combination in First-Line Treatment of Metastatic Nonsqumous NSCLC

Radiation-Based Trimodality Therapy in Stage III NSCLC

Combined Immunotherapy Treatment Studied in Advanced Lung Cancer

Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors

FDA Approves Larotrectinib in Solid Tumors With NTRK Gene Fusion

Palliative and Supportive Care Symposium: Immunotherapy-Related Toxicities

ESMO 2018: Neoadjuvant Erlotinib in Stage IIIA-N2 Lung Cancer

ESMO 2018: Single-Agent Nazartinib in EGFR-Mutant Lung Cancer

ASTRO 2018: Nelfinavir in Stage III Locally Advanced Lung Cancer

ESMO 2018: Resistance Mechanisms in Patients Treated with Osimertinib for Lung Cancer

ESMO 2018: Uncommon EGFR Mutations in Lung Adenocarcinoma

FDA Approves Lorlatinib in ALK-Positive Metastatic NSCLC

FDA Approves Pembrolizumab With Chemotherapy as First-Line Treatment of Metastatic NSCLC

Are Immune-Related Adverse Events Similar in Men and Women?

ASTRO 2018: Survival Benefit Reported With Local Consolidative Therapy in Oligometastatic NSCLC

ESMO 2018: Early Results With Novel Monoclonal Antibody in Advanced Lung Cancer

ESMO 2018: Benefit From Exercise Reported in Advanced Lung Cancer

WCLC 2018: Poziotinib in NSCLC With Genetic Mutations

CHEST 2018: Update on Adherence to Lung Cancer Screening

WCLC 2018: Brigatinib Poised to Become New First-Line Treatment in ALK-Positive Lung Cancer

WCLC 2018: Smoking Cessation Services During Lung Cancer Screening

WCLC 2018: Lorlatinib Active in ROS1-Positive NSCLC

International Cancer Immunotherapy Conference: Early Study Results of Vaccine in HER2-Positive Cancers

WCLC 2018: Survival Benefit With Durvalumab After Chemoradiotherapy in Stage III NSCLC

WCLC 2018: Effect of Nivolumab on Intracerebral Response in NSCLC With Brain Metastases

WCLC 2018: Survival Benefit in Women Compared With Men

WCLC 2018: Immunotherapy for Lung Cancers With Oncogenic Driver Mutations

Dacomitinib Approved by the FDA for Metastatic NSCLC With Genetic Mutations

WCLC 2018: Entrectinib in ROS1-Positive NSCLC

WCLC 2018: Video-Assisted Thoracoscopic Surgery vs. Thoracotomy for Early-Stage Disease

FDA Grants Priority Review to Pembrolizumab as First-Line Treatment in NSCLC Subset

Can m-TORC1/2 Inhibitor Added to Chemotherapy Improve Outcomes in Lung Cancer?

New Therapeutic Strategy for KRAS-Dependent Lung Cancer

RET Inhibitor for NSCLC Granted Breakthrough Therapy Designation by FDA

Can Liquid Biopsy Predict Benefit From Immunotherapy in Lung Cancer?

Building MRI Videos for Planning Lung Cancer Radiotherapy

FDA Approves EGFR-Mutation Test for Use With Gefitinib in NSCLC